Kalbe Farma - Healthy FY25 Growth Outlook Intact Despite ST Rupiah Headwinds
Solid prescription revenue and operating efficiency drove strong 9M24 net and core profit growth of 15.2%/10% yoy. We estimate healthy FY25 net...
192 Views
Kalbe Farma - Improving Growth Outlook from Higher Margins and Steady Revenue
We see catalysts from steady 2H24 revenue (+8.8% yoy), improved margins, & potential FDA approvals for high-margin specialty products.
179 Views
Kalbe Farma - Resilient Growth Outlook at Reasonable Valuation
Unbranded Generic and distribution to drive FY24F top line, while CH and Nutrition revenue normalized. We raised FY24-25F NP by 4.5-2.9%
159 Views
Kalbe Farma (KLBF.IJ) - Resilient Growth Outlook at Reasonable Valuation
Unbranded Generic and distribution to drive FY24F top line, while CH and Nutrition revenue normalized We raised FY24-25F NP by 4.5-2.9%, driven by...
181 Views
Kalbe Farma - Retaining Our Conservative FY24 View
Post FY23 earnings (broadly in-line vs our est.), KLBF guides for further improvements in FY24F revenues/ EPS growth at 6-7% and 13-15% yoy.
220 Views